Predicting the Response of Prostatic Carcinoma to Endocrine Therapy

Ghanadian, R.; Auf, G.; Williams, G.; Davis, Avery; Richards, B.

doi:10.1016/s0140-6736(81)92829-4

Cited by 30 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Median values for Stages A through D for cytosol were 8. 5,9,8,15.0, and 17.5, respectively. For the nucleus, the values were 19.0, 31.8, 38.0, and 44.5, respectively.…”

Section: Resultsmentioning

confidence: 99%

Androgen receptor binding activity in human prostate cancer

Benson

Utz

Holicky

et al. 1985

Cancer

View full text Add to dashboard Cite

Androgen binding (cytosol and nucleus) was measured in tissue obtained from 223 untreated patients with proven prostate cancer (199 primary tumor, 24 malignant lymph nodes), 19 patients with hormone refractory cancer, and 46 patients with benign prostatic hyperplasia (BPH). The mean binding in both the cytosol and nucleus was significantly higher for patients with cancer than for those with BPH. Binding appeared to correlate with tumor stage. Androgen binding in malignant nodes can differ from that in the primary tissue and can vary from node to node in the same patient. Results obtained from an assay using a single saturating concentration of R1881 correlated well with those calculated from a full six‐point Scatchard analysis when an adequate amount (500 mg) of tissue was available. However, binding results obtained from a single‐point analysis performed on needle biopsy specimens (about 50 mg) obtained before complete surgical removal of the prostate correlated poorly with those derived from a full six‐point analysis performed on tissue (500–1000 mg) removed from the center of the malignancy. Androgen binding in nuclear extracts of histologically benign tissue adjacent to the malignancy was significantly higher than in nuclear extracts of BPH tissue. Cytosolic androgen binding in tissue removed from patients who were refractory to hormonal therapy was higher than in tissue from untreated cancer patients. The binding of estradiol by extracts of benign and malignant prostate tissue was low or absent and, thus, did not appear to be a significant phenomenon.

show abstract

“…Median values for Stages A through D for cytosol were 8. 5,9,8,15.0, and 17.5, respectively. For the nucleus, the values were 19.0, 31.8, 38.0, and 44.5, respectively.…”

Section: Resultsmentioning

confidence: 99%

Androgen receptor binding activity in human prostate cancer

Benson

Utz

Holicky

et al. 1985

Cancer

View full text Add to dashboard Cite

show abstract

“…From the standpoint of endocrinology, tissue contents of dihydrotestosterone [14,15] and of androgen receptor [16][17][18][19][20][21][22] also correlate with the response to endocrine therapy and prognosis, since responders usually show better survival rates than patients refractory to the ther apy. In this context, the relationship between pathologi cal grade and contents of dihydrotestosterone and of androgen receptor were examined, but no clear correla tion could be found [23], since heterogeneity in tissue component of prostatic cancer commonly observed may present a problem in accurate grading on tissues [24], Differences of tissue components for pathological exam ination and biochemical one may cause incorrect rela tionship.…”

Section: Discussionmentioning

confidence: 99%

Grade and Histochemical R-1881 Binding in Prostatic Cancer

et al. 1987

View full text Add to dashboard Cite

Comparison of the grades classified by Gleason with R-1881 binding which was attributable to total androphilic proteins in tissues was performed in 42 untreated and 13 relapsed prostatic cancers. Increasing malignancy correlated with loss of staining on R-1881 binding when examined both in primary pattern and in individual tumor cell clusters. In relapsed cancer, however, there was no R-1881 binding irrespective of any grades.

show abstract

“…Nuclear androgen receptors are increasingly being promoted as more useful indicators of hormone dependence (Ghanadian, Auf, Williams et al 1981;Trachtenberg & Walsh, 1982;Brendler et al 1984;Gonor et al 1984;Fentie, Lakey & McBlain, 1986). The earlier studies were restricted to receptors extracted from nuclei at high ionic strength (Ghanadian et al 1981;Trachtenberg & Walsh, 1982). However, a significant nuclear popula¬ tion of androgen receptors resistant to such extrac¬ tions has been located on the nuclear matrix of rat ventral prostate cells (Barrack & Coffey, 1980).…”

Section: Introductionmentioning

confidence: 99%

Intranuclear distribution of androgen receptors in human prostate carcinoma

Kyprianou¹,

Gingell²,

Davies³

1987

Journal of Endocrinology

View full text Add to dashboard Cite

Androgen receptors in nuclei from human prostate carcinomas were characterized on the basis of their solubilization by, or resistance to, micrococcal nuclease. By this means, androgen receptors were assigned to three nuclear categories: those associated with nuclease-resistant structures, those associated with chromatin and those apparently uncommitted by association with either of these. Prostate carcinoma nuclei contained high concentrations (57-82% of total nuclear content) of nuclease-resistant androgen receptors. This was a different pattern from that observed previously for benign hypertrophic prostate epithelial nuclei which contained a variable high proportion of uncommitted androgen receptors. The differences could not be attributed to differential losses to cytosol, or to loss of functionality, as determined in vitro. The differences in distribution could reflect different responses of diseased cells to androgens, or the intervention of other factors more relevant to the disease process.

show abstract

Predicting the Response of Prostatic Carcinoma to Endocrine Therapy

Cited by 30 publications

References 5 publications

Androgen receptor binding activity in human prostate cancer

Androgen receptor binding activity in human prostate cancer

Grade and Histochemical R-1881 Binding in Prostatic Cancer

Intranuclear distribution of androgen receptors in human prostate carcinoma

Contact Info

Product

Resources

About